Overexpression of human epidermal growth factor receptor 2 (HER2) is increasingly recognized as a common molecular abnormality in gastric and gastroesophageal cancer. Drugs targeting the HER2 protein have shown promise in treating these cancers. Additionally, there is evidence to suggest that DS-8201a, an HER2-targeted ADC drug, may be effective and safe in treating patients with heterogeneous or low HER2 expression. To aid in the design of personalized or precise drug treatment strategies for HER2-targeted drugs in clinical trials, Gempharmatech offers suitable patient-derived xenograft (PDX) gastric cancer models.